Medy Tox Inc

Chart & Performance

D1W1MN

P/E

84.98

P/S

3.75

EPS

1,465.12

Div Yield, %

1.02%

Shrs. gr., 5y

1.24%

Rev. gr., 5y

1.48%

Revenues

221.12b

+13.34%

Net income

9.76b

-73.64%

CFO

13.52b

-43.98%

Dividend

Sep 26, 2023952.38098 KRW/sh

Earnings

Mar 05, 2025

Profile

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hyaluronic acid filler products comprising Neuramis and Potenfill that are tissue recovering biomaterials. In addition, it provides various medical devices, such as ComfortDual and Recell Ice for tissue coagulation by using high-frequency current; Neurajet Plus to assist injecting other pharmaceuticals; Carewave for improving erectile dysfunction by using low-intensity shock wave generated from the electromagnetic method; and Careveam for treating skin ailment by using ultraviolet light. Further, the company offers Neurakin cream for acute eczema, contact dermatitis, atopic dermatitis, chronic eczema, rosacea dermatitis, perioral dermatitis, herpes zoster, and acne vulgaris. It also exports its products to approximately 60 countries, including Japan, Thailand, and Brazil. Medytox, Inc. has partnership with Dyadic International, Inc. to develop vaccines against COVID-19 variants. The company was founded in 2000 and is headquartered in Cheongju, South Korea.

URL

http://www.medytox.com/

IPO date

Jan 16, 2009

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title KRW in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title KRW in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	221,120,683 13.34%	195,096,220 5.53%	184,869,548 31.27%
Cost of revenue	173,818,752	118,457,036	127,549,624
Unusual Expense (Income)
NOPBT	47,301,931	76,639,184	57,319,924
NOPBT Margin	21.39%	39.28%	31.01%
Operating Taxes	6,163,181	12,930,301	35,002,682
Tax Rate	13.03%	16.87%	61.07%
NOPAT	41,138,750	63,708,883	22,317,242
Net income	9,755,099 -73.64%	37,009,995 -60.69%	94,153,921 -418.34%
Dividends	(8,422,101)	(8,044,577)
Dividend yield	0.52%	0.96%
Proceeds from repurchase of equity	6,971,148	12,634,207	(8,125,166)
BB yield	-0.43%	-1.50%	0.93%
Debt
Debt current	81,604,285	100,526,465	77,535,829
Long-term debt	2,976,898	20,335,948	55,381,666
Deferred revenue		335,948	1,296,002
Other long-term liabilities	9,128,927	6,256,010	9,328,680
Net debt	(62,339,919)	(105,418,399)	(130,226,663)
Cash flow
Cash from operating activities	13,521,519	24,135,316	16,681,715
CAPEX	(7,659,593)	(25,100,506)	(21,343,637)
Cash from investing activities	13,254,810	(36,472,529)	(28,125,113)
Cash from financing activities	(13,543,577)	(37,974,766)	38,435,325
FCF	23,027,056	34,792,889	29,516,687
Balance
Cash	33,345,129	26,208,405	81,927,217
Long term investments	113,575,972	200,072,407	181,216,940
Excess cash	135,865,067	216,526,001	253,900,680
Stockholders' equity	417,841,516	323,725,331	381,782,894
Invested Capital	430,576,192	336,215,220	279,020,160
ROIC	10.73%	20.71%	7.62%
ROCE	8.35%	13.84%	10.75%
EV
Common stock shares outstanding	6,697	6,565	6,388
Price	241,000.00 88.28%	128,000.00 -6.60%	137,047.63 -13.66%
Market cap	1,613,963,263 92.08%	840,260,864 -4.01%	875,400,782 -14.04%
EV	1,556,863,187	740,656,346	749,530,557
EBITDA	62,677,650	91,949,981	75,575,569
EV/EBITDA	24.84	8.05	9.92
Interest	2,332,980	2,313,515	4,780,682
Interest/NOPBT	4.93%	3.02%	8.34%